GlaxoSmithKline   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Mexico City Mexico (1982)

Organization Overview

First Clinical Trial
1990
NCT01536561
First Marketed Drug
1982
methoxamine (vasoxyl)
First NDA Approval
1985
bupropion (wellbutrin)
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Barrier Therapeutics/ Stiefel, a GSK Company | Bellus Health Inc. - a GSK company | CTI-1, LLC | Darier | GlasoSmithKline | GLAXO GRP ENGLAND | GLAXO GRP LTD | GlaxoSmithKline | GLAXOSMITHKLINE | GlaxoSmithKline AG, Switzerland | GlaxoSmithKline Biologicals | Glaxosmithkline Biologicals S.A. | GLAXOSMITHKLINE CON | GLAXOSMITHKLINE CONS | GlaxoSmithKline (for GlaxoSmithKline; Human Genome Sciences Inc., a GSK Company; Sirtris, a GSK Company; Stiefel, a GSK Company; ViiV Healthcare) | GlaxoSmithKline Intellectual Property Development Ltd. England | GlaxoSmithKline LLC | GlaxoSmithKline, LLC | GLAXOSMITHKLINE LLC | Glaxosmithkline/Quintiles | GlaxoSmithKlline | GSK-CIHR Research Chair in Respiratory Health Care Delivery, | GSK Vaccines Institute for Global Health (GVGH) | GSK Vaccines Institute For Global Health S.r.l. | Stiefel, a GSK Company | Tech Observer